Intuitive Surgical stock holds near recent highs on strong 2025 results

Intuitive Surgical (US46120E6023) is trading against a backdrop of 2025 results that still matter for the stock, with revenue of $8.36 billion for fiscal 2025 and net income of $2.32 billion. The company also reported 1,526 da Vinci systems placed during 2025, a useful scale marker for investors watching installed-base growth.

2025 revenue and profit

The 2025 revenue figure rose from $7.12 billion in 2024, a year-over-year increase of about 17.4%. Net income also increased from $1.82 billion in 2024 to $2.32 billion in 2025, while diluted EPS improved from $4.76 to $5.69 over the same period.

Those numbers matter because Intuitive Surgical remains tied to procedure volumes, system placements, and recurring instrument sales. The fiscal 2025 operating base gives the stock a clear earnings backdrop even when the market is focused on shorter-term price action.

Systems and procedures

Intuitive Surgical said 1,526 da Vinci systems were placed in 2025, taking the installed base further higher. The company also said da Vinci procedures grew 17% in 2025, a quantified comparison that shows the core platform still expanded at a double-digit pace.

For the stock, the combination of a larger installed base and procedure growth is more important than a simple product story. It links the 2025 revenue of $8.36 billion to recurring usage and to the companys longer cash-generation profile.

da Vinci still drives value

The da Vinci platform remains the companys central product line and the main bridge between procedure growth and revenue. In 2025, the system count of 1,526 placements and the 17% procedure growth rate show why the installed base still drives the economics.

That product mix also helps explain why a $8.36 billion revenue base and $2.32 billion in net income can coexist with relatively steady investor attention. The stock tends to react to whether procedure growth and placements stay aligned, not just to one quarter of hardware sales.

Market level and valuation

As of 22 July 2026, the stock is best framed through its recent operating record and its market position rather than a new headline catalyst. The latest evidenced market view in this call is the broader 2025 operating base, which gives a dated comparison point for the share price backdrop.

Intuitive Surgical stock trades in the context of a fiscal 2025 revenue base of $8.36 billion, net income of $2.32 billion, and diluted EPS of $5.69. Those figures, together with 1,526 systems placed in 2025, remain the clearest current anchors for the valuation discussion.

Company snapshot